IL17A and ankylosing spondylitis: ,12–19 Two anti-IL17A monoclonal antibodies were approved for treatment of psoriasis, spondyloarthropathies, psoriatic arthritis, and ankylosing spondylitis,20 although both these antibody therapies had significant side effects.